Global Leading Company
To ensure the well-being and happiness of humanity…
Dong-A ST is a company established in March 2013 following the restructuring of the former Dong-A Pharmaceutical into a holding company.
Our company focuses on the development and sale of specialized pharmaceuticals (ETC) and is dedicated to the philosophy of "Our company's social contribution is in new drug development." With state-of-the-art research facilities such as the Yongin Research Center established in 1977 and the completion of the Songdo Research Center in 2021, Dong-A ST has been striving for innovative global new drug development with excellent research and development capabilities.
For many years, by consistently investing more than 10% of its revenue in R&D, we have successfully developed multiple proprietary novel drugs, including Stillen, Zydena, Motilitone, Sivextro, and Suganon/Sugamet.
What Makes Us
Different?
We have core expertise in developing small molecule compounds. Utilizing our capability and proficiency, we will sequentially release innovative products in this area.
Our mid-to-long term goal is to expand into the field of biopharmaceuticals and gene therapy through domestic and international partnerships. We will devote our efforts to new drug development in the field of oncology and immune system disorders through continuous R&D investment.